Wuhan YZY Biopharma Co Ltd
02496
Company Profile
Business description
Wuhan YZY Biopharma Co Ltd is a biotechnology company dedicated to developing bispecific antibody (BsAb)- based therapies. The Company has been forward-looking in deploying its presence in several therapeutic fields, including but not limited to tumor-associated complications, tumors, ophthalmology, and autoimmune diseases. The Company also proactively established several self-developed technology platforms, such as Y-BODY, Check-Body, and Nano-Ybody, promoting the development of more candidates to clinical stages with high efficiency.
Contact
No. 666 Gaoxin Road
Building C2-1, Optics Valley Bio-City
East Lake High Tech Development Zone
Hubei Province
Wuhan
CHNT: +86 2782668988
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
106
Stocks News & Analysis
stocks
Cheap retail REIT with an attractive yield
Lower consumer spending unlikely to buckle this retail REIT.
stocks
Expanding store network for ASX listed retailer
Sales growth but lack of margin expansion due to competition.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,131.30 | 71.80 | 0.79% |
| CAC 40 | 8,447.27 | 63.26 | 0.75% |
| DAX 40 | 24,910.41 | 16.40 | 0.07% |
| Dow JONES (US) | 51,999.67 | 328.64 | 0.64% |
| FTSE 100 | 10,494.21 | 63.59 | 0.61% |
| HKSE | 24,493.95 | 348.72 | -1.40% |
| NASDAQ | 26,376.34 | 307.60 | -1.15% |
| Nikkei 225 | 69,404.50 | 87.00 | 0.13% |
| NZX 50 Index | 13,426.13 | 0.00 | 0.00% |
| S&P 500 | 7,511.35 | 42.94 | -0.57% |
| S&P/ASX 200 | 8,917.70 | 77.30 | 0.87% |
| SSE Composite Index | 4,091.89 | 4.58 | -0.11% |